

Top Enrolling Physicians for June 2012

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Bonebrake	1	1	.5	1.5
Dr. Carlson	4	3.3	1	4.3
Dr. Cunningham	1	0	1	1
Dr. Holden	1	0	1	1
Dr. Hoos	1	0	1	1
Dr. Nanney	1	1	0	1
Dr. Tiriveedhi	4	4.1	0.1	4.2
TOTALS	14	9.4	4.6	14

We are off to a good start for our new grant year as noted above. Our NCI assigned target credits for grant year 2012-2013 are 110 treatment credits and 80 cancer control credits. To reach our NCI goals we need to earn 9.2 treatment credits and 6.6 control credits each month to meet the assigned target. With just two additional control credits we could have met our goal this month.

Grant Year 2011-2012

Grant year 6/1/2011- 5/31/2012 was a good year for CRO for enrollments to clinical trials. For the first time in 7 years CRO exceeded its NCI assigned target credits. Twenty-six CRO research investigators participated in making this happen. Thanks to all our investigators for participating in our clinical trials. Congratulations to our top four investigators for grant year 2011-2012 listed below:

Physician	Patients Registered	Total Credits Earned
Dr. Carlson	92	35.8
Dr. Bonebrake	51	50.4
Dr. Tiriveedhi	19	15.7
Dr. Ellis	11	8.3

Study Profile

GOG 0244 “The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors and Impact in Newly Diagnosed Patients” was opened at Mercy in June and is going to the IRB at Cox in July. The study co-chair for this study is our own Dr. Jay Carlson. Congratulations Dr. Carlson! Marie Rudolf, the nurse practitioner working with Dr. Carlson will be training research staff at both Cox and Mercy on the proper technique for taking measurements this coming Friday at Dr. Carlson’s office.

Financial Conflict of Interest Policy

On August 24, 2012 the US DHHS will implement revised regulations pertaining to the capturing and reporting of financial conflict of interest (FCOI). These regulations have changed significantly since 1995, including but not limited to a decrease to \$5,000 in the value of equity interest in a public or non-public traded entity; disclosure of any reimbursed or sponsored travel; and a requirement for each investigator to complete FCOI training. These regulations apply to institutions that receive PHS/NIH grants or cooperative agreements. As a recipient of federal monies CRO must abide by these regulations. Policies are currently being developed to assure compliance with these regulations at CRO and its affiliates. All CRO investigators and research staff will be receiving more information about this in the coming month. Research investigators and staff involved with CRO will be required to complete an internet training course and submit any financial conflicts of interest.

Monthly Educational Conferences dates for July

CRO’s educational conference will be on Tuesday, July 10th at 5pm and Monday July 16th at 12noon this month.

New Studies Approved in June 2012

Opened at Cox and Mercy Springfield

RTOG 0929 A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma

Opened at Mercy Springfield Only

GOG-0244 The Lymphedema and Gynecologic Cancer (LEG) Study; Incidence, Risk Factors, and Impact in Newly Diagnosed Patients

Studies Permanently Closed to Enrollment at Cox & Mercy in June 2012

GOG 0207 A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients with Cervical Intraepithelial Neoplasia 3 (CIN 3) (IND#69,656)

GOG 0229J A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND #72740, NSC #732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

MDA 2008-0005 Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients with Metastatic Colorectal Cancer

SWOG S0720 Phase II ERCC 1and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)